MMS Holdings, a data-focused contract research organization (CRO) based in Canton Township, announced the addition of Dr. Robert Allen to its team as principal medical director of global drug safety and pharmacovigilance.
In his new role, Allen will act as senior technical reviewer for complex projects and provide sponsors with medical advice and regulatory support. Within the medical affairs group, he will provide expert guidance on safety surveillance, signal detection, risk evaluation, risk mitigation strategies, medical monitoring, and more while supporting pharmacovigilance colleagues across MMS global operations.
“MMS is synonymous with quality and is a recognized industry leader in supporting clinical development plans all the way through regulatory submissions,” Allen says. “I’m excited to bring my years of diverse drug development, safety, and regulatory experiences to support new and existing MMS clients, with a personal vision and set of goals to provide flawless execution of services, as we strive to bring life-changing therapies to patients around the world.”
Allen has more than 20 years of pharmaceutical industry experience at Parke Davis, Pfizer, Adolor, AstraZeneca, Wyeth, Scirex, Premier, and Inventive/Syneos. In recent years, he has served as chief medical officer for several start-up companies, including Afferent, Centrexion, and Concentric Pharmaceuticals.
“With the addition of Dr. Allen to our Global Drug Safety and Pharmacovigilance team, we will continue to build on our portfolio of clients achieving drug approvals through our regulatory support and expertise. Besides, it will be great to work with Rob again after almost two decades,” says Uma Sharma, founder and chief scientific officer of MMS Holdings.
